Literature DB >> 1347443

Surrogate markers in AIDS: where are we? Where are we going?

S W Lagakos, D F Hoth.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347443     DOI: 10.7326/0003-4819-116-7-599

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  9 in total

1.  An information-theoretic approach to surrogate-marker evaluation with failure time endpoints.

Authors:  Assam Pryseley; Abel Tilahun; Ariel Alonso; Geert Molenberghs
Journal:  Lifetime Data Anal       Date:  2010-09-28       Impact factor: 1.588

2.  Registration of drugs for treating cancer and HIV infection: a plea to carry out phase 3 trials before admission to the market.

Authors:  P P Koopmans
Journal:  BMJ       Date:  1995-05-20

Review 3.  The value of the CD4+ count of 500 cells/microliters.

Authors:  P Volberding
Journal:  Drugs       Date:  1995       Impact factor: 9.546

4.  Novel diagnostic biomarkers for prostate cancer.

Authors:  Chikezie O Madu; Yi Lu
Journal:  J Cancer       Date:  2010-10-06       Impact factor: 4.207

Review 5.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 6.  Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.

Authors:  D Faulds; R N Brogden
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 7.  Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection.

Authors:  S Noble; D Faulds
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

8.  Peripheral blood mononuclear cell human immunodeficiency virus type 1 proviral DNA quantification by polymerase chain reaction: relationship to immunodeficiency and drug effect.

Authors:  J G Montoya; R Wood; D Katzenstein; M Holodny; T C Merigan
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

9.  Surrogate endpoints.

Authors:  S S Ellenberg
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.